CERo Therapeutics Holdings, Inc. (CERO)
$0.01+0.00%Close
SELLCRISIS · day 27
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $12,054
- Beta
- 0.16
- P/E (TTM)
- -0.00
- Short % float
- 1.05%
- Days to cover
- 1.0
- SI change
- +397.5%
- 1W
- +0.00%
- 1M
- +0.00%
- vs SPY 1W
- +0.14%
- vs SPY 1M
- -2.51%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 12
- GROWTH
- 35
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC78.7%
REV YoY-
ROE131.1%
EPS YoY-
ROA-
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.00
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-0.01
P/FCF-
EV/EBITDA-0.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.05
ND/EBITDA-
BETA0.16
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on CERO?
- LOPJLB’s latest quantitative signal on CERo Therapeutics Holdings, Inc. (CERO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CERO in?
- CERo Therapeutics Holdings, Inc. (CERO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does CERo Therapeutics Holdings, Inc. (CERO) do?
- CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartere…